Table 1 Patient characteristics, overall and patients sampled for viral load substudy
Factor | Overall | Viral load substudy |
|---|---|---|
Monitoring randomisation | ||
 LCM | 1,502 (50%) | 882 (50%) |
 CDM | 1,505 (50%) | 880 (50%) |
Gender | Â | Â |
 Male | 1,051 (35%) | 587 (33%) |
 Female | 1,956 (65%) | 1,175 (67%) |
Age at ART initiation (years) Median (IQR) | 37 (32 – 42) | 37 (32 – 43) |
CD4 at ART initiation (cells/mm3) | ||
 Median (IQR) | 86 (32 – 140) | 83 (31 – 137) |
 0-49 | 996 (33%) | 585 (33%) |
 50-99 | 725 (24%) | 440 (25%) |
 100-149 | 687 (23%) | 400 (23%) |
 150-200 | 599 (20%) | 337 (19%) |
Viral load at ART initiation (copies/mL) | ||
 Missing | - | 452 (26%) |
 <30,000 | - | 132 (10%) |
 30,000 – 100,000 | - | 181 (10%) |
 100,000 – 300,000 | - | 373 (21%) |
 300,000 – 700,000 | - | 340 (19%) |
 >700,000 | - | 284 (16%) |
First-line ARTa | ||
 TDF | 2,196 (73%) | 1,104 (63%) |
 NVP | 520 (17%) | 404 (23%) |
 ABC | 291 (10%) | 254 (14%) |
TB in 12Â months prior to enrolment | 737 (25%) | 421 (24%) |
Centre | ||
 Entebbe, Uganda | 914 (30%) | 543 (31%) |
 Kampala, Uganda | 1,159 (39%) | 809 (46%) |
 Harare, Zimbabwe | 934 (31%) | 410 (23%) |
Adherence at week 48 | ||
 0 – 50% | 106 (4%) | 68 (4%) |
 50 – 67% | 175 (6%) | 108 (6%) |
 67 – 75% | 251 (8%) | 152 (9%) |
 75 – 83% | 456 (15%) | 264 (15%) |
 83 – 92% | 876 (29%) | 523 (30%) |
 >92% | 1,134 (38%) | 645 (37%) |
 Missing | 9 (0%) | 2 (0%) |